These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 37370768)

  • 1. Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
    Masson C; Thouvenin J; Boudier P; Maillet D; Kuchler-Bopp S; Barthélémy P; Massfelder T
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
    Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
    Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of gut microbiome in immune modulation in metastatic renal cell carcinoma.
    Deluce J; Maleki Vareki S; Fernandes R
    Ther Adv Med Oncol; 2022; 14():17588359221122714. PubMed ID: 36105887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
    Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
    Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging resistance
    Roy AM; George S
    Cancer Drug Resist; 2023; 6(3):642-655. PubMed ID: 37842239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma.
    Stühler V; Rausch S; Maas JM; Stenzl A; Bedke J
    Expert Opin Biol Ther; 2021 Sep; 21(9):1215-1226. PubMed ID: 33576709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice.
    Lasorsa F; di Meo NA; Rutigliano M; Milella M; Ferro M; Pandolfo SD; Crocetto F; Tataru OS; Autorino R; Battaglia M; Ditonno P; Lucarelli G
    Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis.
    Rizzo A; Mollica V; Santoni M; Massari F
    Expert Rev Gastroenterol Hepatol; 2021 Oct; 15(10):1225-1232. PubMed ID: 34167420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
    Lee HW
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors.
    Delcuratolo MD; Tucci M; Turco F; Di Stefano RF; Ungaro A; Audisio M; Samuelly A; Brusa F; Audisio A; Di Maio M; Scagliotti GV; Buttigliero C
    Crit Rev Oncol Hematol; 2023 Jan; 181():103881. PubMed ID: 36427772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study.
    Zhang H; Chen J; Zhang X; Zhu X; Wang Z; Sun G; Liang J; Chen Y; Shen Y; Liu J; Li X; Wei Q; Liu Z; Zeng H; Shen P
    Immunotherapy; 2022 Apr; 14(5):309-320. PubMed ID: 35187953
    [No Abstract]   [Full Text] [Related]  

  • 15. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular profile of contemporary treatments of renal cell carcinoma: A single-center prospective study.
    Lee K; Lindenfeld L; Echevarria M; Hsu J; Wong FL; Narayan HK; Lau C; Cai L; Pal SK; Armenian SH; Rhee JW
    Int J Cardiol; 2023 Jun; 380():40-46. PubMed ID: 36958393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.
    Raimondi A; Sepe P; Zattarin E; Mennitto A; Stellato M; Claps M; Guadalupi V; Verzoni E; de Braud F; Procopio G
    Front Oncol; 2020; 10():1644. PubMed ID: 32903369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Refractory Metastatic Renal Cell Carcinoma.
    Vento JA; Rini BI
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma.
    Su J; Zhou L; Zhang Z; Xiao X; Qin Y; Zhou X; Huang T
    Front Immunol; 2023; 14():1146738. PubMed ID: 37350955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study.
    Iinuma K; Yamada T; Kameyama K; Taniguchi T; Kawada K; Ishida T; Nagai S; Enomoto T; Ueda S; Takagi K; Kawase M; Takeuchi S; Kawase K; Kato D; Takai M; Nakane K; Koie T
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.